Junshi Out-Licenses Partial China Marketing Rights for PD-1 to AstraZeneca

Shanghai 's Junshi Bio out-licensed certain China marketing rights for its approved PD-1 to AstraZeneca. AstraZeneca will have rights to toripalimab for urothelial carcinoma and other "non-core" indications. According to Junshi, AZN has extensive networks in China , including county-level markets. Junshi has filed an NDA in China for approval of the PD-1 as a second line therapy for bladder cancer. Junshi will continue to market toripalimab for melanoma, its original indication, and will apparently take on other indications as well. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: ASN) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.